Thromboembolic Events in the Era of COVID‐19: A Detailed Narrative Review
Authors:
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2025 (1)
Abstract
COVID‐19, caused by the SARS‐CoV‐2 virus, is not only characterized by respiratory symptoms but is also associated with a wide range of systemic complications, including significant hematologic abnormalities. This is a comprehensive review of the current literature, using PubMed and Google Scholar, on the pathophysiology and incidence of thromboembolic events in COVID‐19 patients and thromboprophylaxis. COVID‐19 infection induces a prothrombotic state in patients through the dysregulation of the renin–angiotensin–aldosterone system (RAAS), endothelial dysfunction, elevated von Willebrand factor (vWF), and a dysregulated immune response involving the complement system and neutrophil extracellular traps (NETs). As a result, thromboembolic complications have emerged in COVID‐19 cases, occurring more frequently in severe cases and hospitalized patients. These thrombotic events affect both venous and arterial circulation, with increased incidences of deep venous thrombosis (DVT), pulmonary embolism (PE), systemic arterial thrombosis, and myocardial infarction (MI). While DVT and PE are more common, the literature highlights the potential lethal consequences of arterial thromboembolism (ATE). This review also briefly examines the ongoing discussions regarding the use of anticoagulants for the prevention of thrombotic events in COVID‐19 patients. While theoretically promising, current studies have yielded varied outcomes: Some suggest potential benefits, whereas others report an increased risk of bleeding events among hospitalized patients. Therefore, further large‐scale studies are needed to assess the efficacy and safety of anticoagulants for thromboprophylaxis in COVID‐19 patients.Keywords
This publication has 141 references indexed in Scilit:
- Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopeniaImmunity, Inflammation and Disease, 2023
- Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19JAMA Network Open, 2023
- Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19JAMA Internal Medicine, 2022
- COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- The pooled prevalence of pulmonary embolism in patients with COVID-19Intensive Care Medicine, 2020
- High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort studyIntensive Care Medicine, 2020
- Physiological Roles of the von Willebrand Factor-Factor VIII Interaction2020
- Critical role of C5a in sickle cell diseaseAmerican Journal of Hematology, 2018
- The coagulation system in host defenseResearch and Practice in Thrombosis and Haemostasis, 2018
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004